The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) for the treatment of Crohn’s ...

Janssen-Cilag Limited has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya, Janssen-Cilag Limited) for use in adults with Crohn’s disease and ulcerative colitis (UC).

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) to treat Crohn’s disease and ulcerative colitis (UC). The approval was granted on 16th May, 2025 to ...

Patients with severe bowel disease are set to benefit from a new drug that can eliminate their distressing symptoms in only ...

Johnson & Johnson (J&J) has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for its ...

A Phase 2/3, randomised, double-blind, placebo- and active-controlled, parallel-group, multicentre protocol to evaluate the efficacy and safety of guselkumab in participants with moderately to ...

Guselkumab European Commission approval in Crohn's disease builds upon recent ulcerative colitis approval, 4 marking the fourth indication for this dual-acting IL-23 inhibitor in the European Union.

Guselkumab can be administered either by intravenous infusion or injection for the initial treatment of Crohn’s disease. For UC, initial treatment will be administered via an intravenous infusion.